

ENANTIOSPECIFIC SYNTHESIS OF R- AND S-5,6-DIHYDROXY-2-(N,N-DI-*n*-PROPYLAMINO)TETRALINS FROM SERINE.

A. D. Baxter, P. J. Murray


Glaxo Group Research Ltd, Park Road, Ware, Hertfordshire, SG12 ODP, England.

R. J. K. Taylor

School of Chemical Sciences, University of East Anglia, Norwich, NR4 7TJ, England.

Abstract: The first enantiospecific synthesis of 5,6-dihydroxy-2-(N,N-di-*n*-propylamino)tetralin [5,6-(HO)₂DPAT] is reported. Starting from D- or L-serine either enantiomer is readily available in high optical purity.


Drugs acting on central dopamine D₂ receptors are known to be of clinical interest in the treatment of schizophrenia and Parkinson's disease.¹ 5,6-Dihydroxy-2-(N,N-di-*n*-propylamino)tetralin (S-5,6-(HO)₂DPAT) (1) is a potent D₂ receptor agonist and hence an important pharmacological tool. 5,6-(HO)₂DPAT (1) has been prepared in racemic form² and subsequently resolved using (+)- and (-)-dibenzoyltartaric acid.³



Previous enantiospecific syntheses of aminotetralins have been achieved from the aspartic anhydride derivatives (2)⁴ and (3)⁵ by means of a Friedel-Crafts acylation procedure. Acylation of catechol with the aspartic anhydride derivative (3) occurs in the 4-position and ultimately leads to a synthesis of the regioisomeric 6,7-(HO)₂DPAT (4). This reagent is therefore unsuitable for the preparation of (1). We report here an alternative general strategy for the enantiospecific synthesis of aminotetralins starting from serine. This procedure also provides an efficient method for the preparation of *homo*-phenylalanine derivatives.

The aldehyde (**5**) is configurationally stable⁶ and has been widely used in synthesis.⁷ We now report the first synthesis and use of the more robust aldehyde (**6**) which is compatible with all the conditions employed in our synthesis of 5,6-(HO)₂DPAT. Thus the aldehyde derivative (**6**) was prepared from D-serine (scheme 1) and has been shown to be configurationally stable by hplc analysis of the Mosher's ester derivative (**7**).⁸ The most convenient preparation of (**6**) proved to be lithium borohydride reduction of the ester (**8**) followed by Swern oxidation. DIBAL reduction of (**8**), although more direct, proceeded in low yield.

Scheme 1




Reagents and conditions:

a) MeOH, HCl, reflux, 18h, 100%. b) ClCO₂Me, NaHCO₃, H₂O, 5°C, 1h, 80%. c) 2,2-Dimethoxypropane, TsOH, toluene, reflux, 2h, 75%. d) DIBAL, toluene, -78°C, 1h, 20%. e) LiBH₄, THF, room temperature, 18h, 80%. f) (COCl)₂, DMSO, CH₂Cl₂, -65°C; N-methylmorpholine, 70%. g) NaBH₄, THF, *i*-PrOH, 0°C, 2h, 90%. h) (S)-MTPA, DCC, DMAP, CH₂Cl₂, room temperature, 6h, 92%.

Wittig reaction of (**6**) with the known phosphonium salt (**9**)⁹ produced a mixture of olefins (E:Z, *ca.* 60:40), which were hydrogenated. Hydrolysis of the acetonide, followed by PDC oxidation of the resulting alcohol then provided the *homo*-phenylalanine derivative (**10**) in good yield.

Acid chloride formation under mild conditions, followed by intramolecular Friedel-Crafts acylation using titanium tetrachloride as the catalyst, produced a stable ketone which was deoxygenated with triethylsilane to the carbamate (**11**) (>98% e.e. by hplc analysis).⁸

Scheme 2



Reagents and conditions:

a) (9), *t*-BuOK, THF, 0°C, 2h, 100%. b) H₂, Pd-C, EtOAc, 2h, 100%. c) TsOH, MeOH, room temperature, 18h, 84%. d) PDC, DMF, room temperature, 6h, 56%. e) (COCl)₂, cat. DMF, CH₂Cl₂, 0°C; TiCl₄, CH₂Cl₂, 0°C - room temperature, 2h, 80%. f) Et₃SiH, BF₃·OEt₂, room temperature, 18h, 59%. g) KOH, MeOH, H₂O, reflux, 18h, 86%. h) NaBH(OAc)₃, EtCHO, HOAc, ClCH₂CH₂Cl, room temperature, 2h, 92%. i) BBr₃, CH₂Cl₂, room temperature, 18h, 89%.

Hydrolysis of the carbamate protecting group, followed by reductive dialkylation using sodium triacetoxyborohydride and propionaldehyde, then finally boron tribromide deprotection of the methyl ether groups furnished S-(-)-5,6-(HO)₂DPAT (1) in 5% overall yield from serine. [Mp of hydrochloride salt, 168-171°C; Lit.³ mp 170-171°C. [α]_D²⁰ -54.7° (c = 0.3, H₂O); Lit.³ [α]_D²⁰ -51.7° (c = 0.15, H₂O)]. In a similar procedure L-serine was converted to the isomerically pure R-(+)-5,6-(HO)₂DPAT. [Mp of hydrochloride salt, 168-172°C. [α]_D²⁰ +48.4° (c = 0.8, H₂O); Lit.³ [α]_D²⁰ +48.8° (c = 0.15, H₂O)].

References and notes:

1. E. Flückiger (Ed), "Basic and Clinical Aspects of Neuroscience; The Role of Brain Dopamine."; Springer-Verlag: Berlin, 1989, vol. 3.
2. J. D. McDermed, G. M. McKenzie, and A. P. Phillips; *J. Med. Chem.*, 1975, 18, 362.

3. C. J. Grol, L. J. Jansen, and H. Rollema; *J. Med. Chem.*, **1985**, *28*, 679.
4. J. E. Norlander, M. J. Payne, F. G. Njorge, V. M. Vishwanath, G. R. Han, G. D. Laitos, and M. A. Balk; *J. Org. Chem.*, **1985**, *50*, 3619.
5. D. G. Melillo, R. D. Larsen, D. J. Mathre, W. F. Shukis, A. W. Wood, and J. R. Colleluori; *J. Org. Chem.*, **1987**, *52*, 5143.
6. P. Garner and J. M. Park; *J. Org. Chem.*, **1987**, *52*, 2361.
7. a) P. Garner; *Tetrahedron Lett.*, **1984**, *25*, 5855. b) T. Moriwake, S. Saito, S. Hamano, and S. Torri; *Chem. Lett.*, **1987**, 2085. c) P. Herold; *Helv. Chim. Acta.*, **1988**, *71*, 354. d) A. Dondoni, G. Fantin, M. Fogagnolo, and P. Pedrini; *J. Chem. Soc., Chem. Commun.*, **1988**, 10. e) P. Garner and J. M. Park; *J. Org. Chem.*, **1990**, *55*, 3772.
8. For hplc analyses of (7) and (11), the authors are indebted to Mr R. J. Boughtflower and his colleagues in the Structural Chemistry Department at Glaxo Group Research, Ware.
9. M. V. Sargent, S. Wangchareontrakul, and A. Jefferson; *J. Chem. Soc., Perkin Trans. 1*, **1977**, 190.

(Received in USA 20 January 1992)